Operating margin has swung widely from -2.3% to -192.6% across ten quarters, a range that suggests reported results reflect R&D and SG&A timing more than any stable cost structure. The recent improvement to -132.0% coincides with R&D expense falling 42% year-over-year to $17.4M, per disclosed income statements, implying the company is engineering loss reduction through retrenchment rather than achieving operating leverage on a growing commercial base. Adjusting for stock-based compensation of approximately $25.8M cumulative over the series, the underlying cash operating loss remains materially larger than headline figures suggest, and gross profit of $16.9M in 2026Q2 still falls well short of combined R&D and SG&A.

With a negative P/E of -1.45 and no meaningful EV/EBITDA (loss-making), the P/S of 2.53 is the only available earnings-independent valuation anchor, yet it does not distinguish between cash on the balance sheet and revenue-generating operations. Given that ADCT's enterprise value is depressed by $219.1M in cash against $417.1M in total debt, the effective EV/Sales implied by the P/S would be materially higher once net debt is factored in, which warrants closer investigation. Relative to peers RCUS (market cap $2.3B, ROE -88%) and MGNX ($157M, ROE -31.3%), ADCT's valuation appears to price in near-term financing runway rather than commercial traction, a dynamic investors should monitor alongside the deferred revenue volatility disclosed in recent quarters.

The debt structure oscillates between $116.7M and $449.9M across ten quarters, a pattern consistent with a revolving facility being drawn and repaid rather than a stable term-loan amortization schedule, which means refinancing risk is embedded in the capital structure itself. With shareholders' equity at -$228.2M and an accumulated deficit approaching $1.7B, traditional leverage ratios (D/E) are mathematically meaningless, and the effective risk profile is better understood as an unsecured funding obligation against a depleting cash balance. Interest coverage has been negative in eight of the last ten quarters, the sole exception being 2025Q4 at 0.48 — a level that itself signals the company barely covers interest even in its strongest period — suggesting that covenant compliance and refinancing capacity warrant close monitoring.

The quick ratio of 2.97 in 2026Q2 is nearly identical to the current ratio, confirming minimal inventory dependence and that liquidity is essentially a cash-and-receivables story, with DSO of 140 days suggesting receivables collection is slow and vulnerable to customer concentration risk. Cumulative free cash flow burn of approximately $308M over ten quarters implies a quarterly burn rate averaging $30.8M, though the most recent quarter's $11.8M outflow suggests burn has slowed alongside cost cuts; at that reduced pace, $219.1M in cash represents roughly 18 quarters of runway, but a return to prior burn rates would compress that materially. The binary pattern in deferred revenue — swinging from $322.6M to zero across recent quarters — may introduce lumpiness into both liquidity and revenue recognition, which investors should factor into stress-case liquidity modeling.